Amarantus Bioscience Holdings Inc (AMBS)

[redspeed]

Why has the company been unable to secure any Non Dilutive funding or any major grants (when Bio companies across the industry are doing so)?

Good intelligent question. My take:

F. Randall Grimes was hired two years ago to do just that. He had a track, record especially around Lympro. For whatever reason, it appears he came up short. Does that make GC a liar. Not in my book. Is everyone disappointed including me. Yes.

http://globenewswire.com/news-release/2013/09/13/573410/10048467/en/Amarantus-Appoints-F-Randall-Grimes-MBA-as-Director-of-Sponsored-Research.html

(when Bio companies across the industry are doing so)?

Not so sure about that. The ones that do, are usually a little further along. Tx also grabs more the the attention & dollars that Dx. I think GC said that in a CC or blog as well.

When you are a penny stock everyone wants to take advantage of you. It's the Shark Tank premise. The assumption is you are desperate for money and will agree to anything or go out of business. IBs/VCs look at tons of deals. They don't cry over the ones that didn't take a low ball offer.

But based on their dire need and precarious financial situation

It appears dire, but is it? I don't know. The analysts seem to think the company is worth potentially more. Wonder what the IB think. They are the ones that matter. I'll believe dire when they dump an asset for half of it's value.



To support the theory that the companies that are getting funding are a little further along, I posted before about AGTC which has parallels to Amarantus MANF Ophthalmology. Now that AMBS has two MANF orphans, this is why they get excited. Note AGTC doesn't have ESS, Elto, Dx, etc.


AGTC is at an early stage in their ophthalmology programs (RP, AMD, etc.) but this will give an idea of what it's worth even now.


AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed

Under the terms of the agreements, Biogen will make near-term payments including an upfront payment in the amount of $124 million to AGTC, which includes a $30 million equity investment at a purchase price of $20.63 per share. AGTC is eligible to receive upfront and milestone payments exceeding $1 billion in total. Biogen will be granted a license to the XLRS and XLRP programs and the option to license discovery programs for three additional indications at the time of clinical candidate selection.

http://finance.yahoo.com/news/agtc-announces-strategic-collaboration-biogen-200500623.html


AGTC has five ongoing ophthalmology development programs and proof-of-concept data in multiple indications.

http://www.agtc.com/products